Q2 2025 Thyrocare Technologies Ltd Earnings Call Transcript
Key Points
- Thyrocare Technologies Ltd (BOM:539871) achieved a record high revenue of INR177.4 crore this quarter, surpassing even their peak during the COVID period.
- The company reported a 20% year-on-year revenue growth, primarily driven by their pathology business.
- Thyrocare Technologies Ltd (BOM:539871) has successfully expanded its franchise network to 8,400 active franchisees, processing 6.7 million samples and serving 4.4 million patients this quarter.
- The company has completed strategic acquisitions, including Polo Labs and Winter Labs, to expand its footprint in North and South India.
- Thyrocare Technologies Ltd (BOM:539871) has been recognized by the College of American Pathologists for maintaining excellence in high-quality laboratory care for over 15 years.
- The partnerships business, while growing, operates at a lower margin compared to the franchise business.
- Employee expenses have increased year-on-year due to annual increments and headcount increases from new business acquisitions.
- The company faces margin pressure from recent acquisitions and geographical expansions.
- There is uncertainty regarding the impact of potential GST changes on the health insurance segment, which could affect pricing and customer costs.
- The company is still in the early stages of integrating recent acquisitions, such as Winter Labs, which are currently close to break-even or slightly negative in EBITDA margins.
Ladies and gentlemen, good day and welcome to Thyrokare Technologies Limited earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Kapil Gupta from Thyrocare Technologies Limited. Thank you and over to you Mr. Kapil.
Thank you. Ruthuja. A very good evening to all and thank you for joining us today for the Thyrocare earnings conference call for the second quarter of FY25. Today, we have with us Mr. Rahul Guha, MD and CEO of Thyrocare; Mr. Alok Jagnani, CFO of Thyrocare; and Mr. Nitin Chugh, Chief Commercial Officer of Thyrocare, along with other key members of the senior management on this call to share highlights of the business and financials for the quarter.
I hope you have gone through our quarterly results, press release and earning presentation which has now been uploaded on the stock exchange website. The transcript of this call will be available in a week's time on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
